Search Results

Rigo is a Licensed Master Social Worker (LMSW) with over ten years of clinical experience supporting individuals and families across inpatient and outpatient behavioral health settings. He has a compassionate approach, strong clinical judgment, and commitment to ethical, client-centered care, specializing in comprehensive assessments, crisis intervention, treatment planning, and effective collaboration within multidisciplinary clinical teams.…

A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17, D763QC00001) MOA: Datopotamab Deruxtecan (Dato-DXd) is an ADC targeting TROP2 containing a topoisomerase I inhibitor payload Key Eligibility Criteria: Documented Stage IIIB, IIIC, or Stage IV…

A Multicenter, randomized, open label, Phase 3 Trial of Trastuzumab Deruxtecan (ENHERTU®) plus chemotherapy plus or minus Pembrolizumab versus chemotherapy plus Trastuzumab plus or minus Pembrolizumab as first line treatment in participants with unresectable, locally advanced or metastatic HER2-postive Gastric or GEJ cancer. (Destiny- Gastric05) (Trial of Trastuzumab Deruxtecan (ENHERTU®) plus chemotherapy plus or minus…

NX-5948-201: A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton’s Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i) MOA: NX-5948 (bexobrutideg) is a CTM that induces the degradation of BTK in cells through…